NIH to Launch New On-Line Repository for Life Sciences Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

BETHESDA, Md-The new year will bring a new and controversial source for obtaining access to new scientific studies in the life sciences. In January, the National Institutes of Health (NIH) will launch PubMed Central, a free on-line repository of research reports, found at http://www.ncbi.nlm.nih.gov/PubMed/.

BETHESDA, Md—The new year will bring a new and controversial source for obtaining access to new scientific studies in the life sciences. In January, the National Institutes of Health (NIH) will launch PubMed Central, a free on-line repository of research reports, found at http://www.ncbi.nlm.nih.gov/pubmed/.

The site will store, organize, and distribute articles, preprints, and screened reports contributed to the repository by scientific journals and “reputable scientific organizations.” It is unclear, however, to what extent peer-reviewed journals will cooperate with the new venture.

PubMed Central is an expanded form of E-biomed, which NIH director Harold E. Varmus, MD, originally proposed in May as a cyberspace library for the biomedical sciences. His idea drew considerable criticism from companies and organizations that publish scientific journals, which feared the free service would cost them subscribers. The plan was also criticized for the use of materials that were not peer reviewed.

Recent Videos
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content